A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Prior treatment

• Participants had prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor.
• Participants had undergone an allogeneic hematopoietic stem cell transplantation within 12 months of enrollment.
• Participants had undergone major surgery within 4 weeks prior to the start of study treatment.

Other illness

• Participants had a prior malignancy within the past 2 years, except for those who had curatively treated basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized prostate cancer with a Gleason score of 6.
• Participants had clinically significant cardiovascular disease.
• Participants had an active fungal, bacterial, or viral infection requiring systemic treatment.
• Participants had a history of severe bleeding disorder.
  • Note: Other protocol-defined inclusion and exclusion criteria may have applied.

Other

• Participants had known central nervous system involvement by leukemia or lymphoma.
• Participants had evidence of transformation from follicular lymphoma to another aggressive histologic subtype.

• Participants had a histologically confirmed diagnosis of B-cell follicular lymphoma.
• Participants had received two or more prior systemic treatments for follicular lymphoma.
• Participants had previously received both an anti-cluster of differentiation 20 (anti-CD20) antibody and an appropriate alkylator-based combination therapy.
• Participants had disease that had progressed after completion of the most recent therapy or was considered refractory to treatment.
• Participants had measurable disease present.
• Archival tissue confirming the diagnosis was available.
• Participants had an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Participants had adequate renal and hepatic function.